Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer

Lawrence Einhorn, Patrick Loehrer, S. D. Williams, S. Meyers, T. Gabrys, S. R. Nattan, R. Woodburn, R. Drasga, J. Songer, W. Fisher

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

In this phase III randomized study, 124 evaluable patients with unresectable non-small-cell lung cancer (NSCLC) were randomized to vindesine v cisplatin (120 mg/m2) plus vindesine v cisplatin (60 mg/m2) plus vindesine plus mitomycin C. The objective response rate for cisplatin and vindesine was 27% v 20% for cisplatin, vindesine, and mitomycin C, and 14% for vindesine alone (P = .25 for cisplatin and vindesine v vindesine). The percentage of patients having stable disease (no progression for a minimum of 3 months) was 20% (cisplatin and vindesine), 27% (cisplatin, vindesine, and mitomycin C), and 26% (vindesine alone), respectively. The median survival time for vindesine was 18 weeks, compared with 26 weeks for cisplatin and vindesine and 17 weeks for cisplatin, vindesine, and mitomycin C. Overall survival was not statistically different for cisplatin plus vindesine v vindesine (P = .65). There was no evidence for improved duration of remission or survival of responders with the cisplatin (120 mg/m2) and vindesine arm. This study failed to demonstrate sufficient therapeutic benefit for cisplatin and vindesine (± mitomycin C) compared with single-agent vindesine to justify the increased cost and toxicity of these combination regimens.

Original languageEnglish
Pages (from-to)1037-1043
Number of pages7
JournalJournal of Clinical Oncology
Volume4
Issue number7
StatePublished - 1986

Fingerprint

Vindesine
Mitomycin
Non-Small Cell Lung Carcinoma
Cisplatin
Prospective Studies
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. / Einhorn, Lawrence; Loehrer, Patrick; Williams, S. D.; Meyers, S.; Gabrys, T.; Nattan, S. R.; Woodburn, R.; Drasga, R.; Songer, J.; Fisher, W.

In: Journal of Clinical Oncology, Vol. 4, No. 7, 1986, p. 1037-1043.

Research output: Contribution to journalArticle

Einhorn, Lawrence ; Loehrer, Patrick ; Williams, S. D. ; Meyers, S. ; Gabrys, T. ; Nattan, S. R. ; Woodburn, R. ; Drasga, R. ; Songer, J. ; Fisher, W. / Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. In: Journal of Clinical Oncology. 1986 ; Vol. 4, No. 7. pp. 1037-1043.
@article{856ffbe9431045d382c97ecd5f9755d0,
title = "Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer",
abstract = "In this phase III randomized study, 124 evaluable patients with unresectable non-small-cell lung cancer (NSCLC) were randomized to vindesine v cisplatin (120 mg/m2) plus vindesine v cisplatin (60 mg/m2) plus vindesine plus mitomycin C. The objective response rate for cisplatin and vindesine was 27{\%} v 20{\%} for cisplatin, vindesine, and mitomycin C, and 14{\%} for vindesine alone (P = .25 for cisplatin and vindesine v vindesine). The percentage of patients having stable disease (no progression for a minimum of 3 months) was 20{\%} (cisplatin and vindesine), 27{\%} (cisplatin, vindesine, and mitomycin C), and 26{\%} (vindesine alone), respectively. The median survival time for vindesine was 18 weeks, compared with 26 weeks for cisplatin and vindesine and 17 weeks for cisplatin, vindesine, and mitomycin C. Overall survival was not statistically different for cisplatin plus vindesine v vindesine (P = .65). There was no evidence for improved duration of remission or survival of responders with the cisplatin (120 mg/m2) and vindesine arm. This study failed to demonstrate sufficient therapeutic benefit for cisplatin and vindesine (± mitomycin C) compared with single-agent vindesine to justify the increased cost and toxicity of these combination regimens.",
author = "Lawrence Einhorn and Patrick Loehrer and Williams, {S. D.} and S. Meyers and T. Gabrys and Nattan, {S. R.} and R. Woodburn and R. Drasga and J. Songer and W. Fisher",
year = "1986",
language = "English",
volume = "4",
pages = "1037--1043",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer

AU - Einhorn, Lawrence

AU - Loehrer, Patrick

AU - Williams, S. D.

AU - Meyers, S.

AU - Gabrys, T.

AU - Nattan, S. R.

AU - Woodburn, R.

AU - Drasga, R.

AU - Songer, J.

AU - Fisher, W.

PY - 1986

Y1 - 1986

N2 - In this phase III randomized study, 124 evaluable patients with unresectable non-small-cell lung cancer (NSCLC) were randomized to vindesine v cisplatin (120 mg/m2) plus vindesine v cisplatin (60 mg/m2) plus vindesine plus mitomycin C. The objective response rate for cisplatin and vindesine was 27% v 20% for cisplatin, vindesine, and mitomycin C, and 14% for vindesine alone (P = .25 for cisplatin and vindesine v vindesine). The percentage of patients having stable disease (no progression for a minimum of 3 months) was 20% (cisplatin and vindesine), 27% (cisplatin, vindesine, and mitomycin C), and 26% (vindesine alone), respectively. The median survival time for vindesine was 18 weeks, compared with 26 weeks for cisplatin and vindesine and 17 weeks for cisplatin, vindesine, and mitomycin C. Overall survival was not statistically different for cisplatin plus vindesine v vindesine (P = .65). There was no evidence for improved duration of remission or survival of responders with the cisplatin (120 mg/m2) and vindesine arm. This study failed to demonstrate sufficient therapeutic benefit for cisplatin and vindesine (± mitomycin C) compared with single-agent vindesine to justify the increased cost and toxicity of these combination regimens.

AB - In this phase III randomized study, 124 evaluable patients with unresectable non-small-cell lung cancer (NSCLC) were randomized to vindesine v cisplatin (120 mg/m2) plus vindesine v cisplatin (60 mg/m2) plus vindesine plus mitomycin C. The objective response rate for cisplatin and vindesine was 27% v 20% for cisplatin, vindesine, and mitomycin C, and 14% for vindesine alone (P = .25 for cisplatin and vindesine v vindesine). The percentage of patients having stable disease (no progression for a minimum of 3 months) was 20% (cisplatin and vindesine), 27% (cisplatin, vindesine, and mitomycin C), and 26% (vindesine alone), respectively. The median survival time for vindesine was 18 weeks, compared with 26 weeks for cisplatin and vindesine and 17 weeks for cisplatin, vindesine, and mitomycin C. Overall survival was not statistically different for cisplatin plus vindesine v vindesine (P = .65). There was no evidence for improved duration of remission or survival of responders with the cisplatin (120 mg/m2) and vindesine arm. This study failed to demonstrate sufficient therapeutic benefit for cisplatin and vindesine (± mitomycin C) compared with single-agent vindesine to justify the increased cost and toxicity of these combination regimens.

UR - http://www.scopus.com/inward/record.url?scp=0022535968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022535968&partnerID=8YFLogxK

M3 - Article

C2 - 3088219

AN - SCOPUS:0022535968

VL - 4

SP - 1037

EP - 1043

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -